WO2026091339 - CHIDAMIDE POLYMORPH I AND PREPARATION METHOD THEREFOR
National phase entry is expected:
Publication Number
WO/2026/091339
Publication Date
07.05.2026
International Application No.
PCT/CN2025/079154
International Filing Date
26.02.2025
Title **
[English]
CHIDAMIDE POLYMORPH I AND PREPARATION METHOD THEREFOR
[French]
POLYMORPHE I DE CHIDAMIDE ET SON PROCÉDÉ DE PRÉPARATION
[Chinese]
西达本胺晶型I及其制备方法
Applicants **
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Inventors
GU, Huike
WANG, Leixin
LIN, Kai
QIAO, Zhitao
WANG, Ying
Priority Data
202411517085.0
29.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1575 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1788 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,743
Contact Us
Abstract[English]
The present invention relates to the field of pharmaceutical polymorphs, and specifically relates to a chidamide polymorph I and a preparation method therefor. The chidamide polymorph I has good stability, fluidity, solubility and bioavailability, and low hygroscopicity, has the advantage of being manufactured as a drug, and can be developed as a pharmaceutical polymorph. The preparation method for the polymorph I is simple, has good repeatability and high yield, is easy to operate, is environmentally friendly, requires a small amount of solvent, is beneficial to recycling, can effectively reduce reagent costs, and is easy to realize large-scale production.[French]
La présente invention relève du domaine des polymorphes pharmaceutiques, et concerne en particulier un polymorphe I de chidamide et son procédé de préparation. Le polymorphe I de chidamide présente une bonne stabilité, une bonne fluidité, une solubilité et une biodisponibilité, et une faible hygroscopicité, a l'avantage d'être fabriqué en tant que médicament, et peut être développé en tant que polymorphe pharmaceutique. Le procédé de préparation du polymorphe I est simple, a une bonne répétabilité et un rendement élevé, est facile à utiliser, est respectueux de l'environnement, nécessite une petite quantité de solvant, est bénéfique pour le recyclage, peut réduire efficacement les coûts de réactifs, et est facile à réaliser une production à grande échelle.[Chinese]
本发明涉及药物晶型领域，具体涉及一种西达本胺的晶型I及其制备方法；所述西达本胺的晶型I具有较好的稳定性、流动性、溶解度以及良好的生物利用度和较低的引湿性，具备成药优势，可以作为药用晶型开发；所述晶型I的制备方法简单重复性好，收率高，易于操作，绿色环保，所需溶剂量小且有利于回收利用，能够有效降低试剂成本，容易实现规模化放大生产。